Jazz Pharmaceuticals Quarterly Balance Sheet
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals financial position
As of Jun 30, 2026, Jazz Pharmaceuticals reported total assets of $11.08 billion, up 1.2% from a year earlier against total liabilities of $6.28 billion. Shareholders' equity stood at $4.80 billion, or 43.3% of assets. The company held $1.62 billion in cash and equivalents against $4.35 billion of debt, a net debt position of $2.73 billion.
The current ratio (current assets divided by current liabilities) was 1.78, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.91.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.62B | 1.84B | 1.39B | 1.33B | 1.19B | 1.86B | 2.41B | 2.22B | 1.36B | 1.44B | 1.51B | 1.34B |
| Receivables | 880.90M | 836.30M | 830.70M | 764.36M | 714.00M | 652.99M | 716.76M | 723.64M | 698.04M | 707.10M | 705.79M | 627.84M |
| Inventory | 443.00M | 437.50M | 417.00M | 483.11M | 504.99M | 492.78M | 480.44M | 539.30M | 542.55M | 577.32M | 597.04M | 611.83M |
| Total Current Assets | 3.97B | 4.58B | 4.17B | 3.76B | 3.35B | 4.13B | 4.63B | 4.39B | 3.68B | 3.54B | 3.44B | 3.25B |
| Property, Plant & Equipment | 212.00M | 203.10M | 199.90M | 188.91M | 184.97M | 178.87M | 173.41M | 176.42M | 169.28M | 166.24M | 169.65M | 222.48M |
| Goodwill | 1.80B | 1.80B | 1.83B | 1.83B | 1.84B | 1.76B | 1.72B | 1.80B | 1.74B | 1.74B | 1.75B | 1.71B |
| Intangible Assets | 4.03B | 4.20B | 4.43B | 4.57B | 4.77B | 4.72B | 4.76B | 5.14B | 5.08B | 5.24B | 5.42B | 5.42B |
| Total Assets | 11.08B | 11.86B | 11.66B | 11.36B | 10.94B | 11.53B | 12.01B | 12.26B | 11.36B | 11.33B | 11.39B | 11.20B |
| Accounts Payable | 128.50M | 100.00M | 122.10M | 152.23M | 89.37M | 95.93M | 77.87M | 85.42M | 97.10M | 80.98M | 102.75M | 109.85M |
| Short-Term Debt | 1.02B | 1.03B | 1.03B | 1.03B | 1.03B | 31.00M | 31.00M | 31.00M | 605.80M | 605.38M | 604.95M | 604.51M |
| Total Current Liabilities | 2.23B | 2.25B | 2.24B | 2.27B | 2.07B | 1.22B | 1.04B | 1.03B | 1.56B | 1.56B | 1.54B | 1.57B |
| Long-Term Debt | 3.33B | 4.32B | 4.33B | 4.33B | 4.34B | 5.34B | 6.08B | 6.08B | 5.10B | 5.11B | 5.11B | 5.11B |
| Total Liabilities | 6.28B | 7.33B | 7.34B | 7.40B | 7.24B | 7.36B | 7.92B | 8.08B | 7.60B | 7.63B | 7.66B | 7.71B |
| Shareholders' Equity | 4.80B | 4.53B | 4.32B | 3.96B | 3.71B | 4.17B | 4.09B | 4.17B | 3.76B | 3.70B | 3.74B | 3.49B |
| Retained Earnings | 1.13B | 939.20M | 646.10M | 442.73M | 191.31M | 1.03B | 1.13B | 936.23M | 871.18M | 864.04M | 878.66M | 884.30M |
| Total Debt | 4.35B | 5.35B | 5.36B | 5.36B | 5.36B | 5.37B | 6.11B | 6.11B | 5.71B | 5.71B | 5.71B | 5.72B |
| Net Cash (Debt) | -2.73B | -3.51B | -3.97B | -4.04B | -4.17B | -3.51B | -3.70B | -3.89B | -4.35B | -4.27B | -4.21B | -4.38B |
| Shares Outstanding | — | — | 61.44M | — | — | — | 60.63M | — | — | — | 62.26M | — |
This table shows 12 quarterly periods of Jazz Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow JAZZ's reporting calendar. What is a balance sheet?